In TP53-aberrant CLL/MCL patients, therapy aims to block the B-cell receptor pathway with Bruton tyrosine kinase (BTK) inhibitors or B-cell lymphoma-2 (bcl2) inhibitors, which act independently of the TP53 pathway as opposed to treatment with cytotoxic agents [9, 10]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.